Press Releases
Samsung Biologics joins strategic investment in Araris to support collaboration in ADC therapies
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures, makes investment in Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.
The latest investment reflects Samsung Biologics’ commitment to further expand its pipeline and explore new opportunities in biopharmaceuticals, wherein Samsung affiliates will work with Araris to evaluate, manufacture and develop assets using the biotech’s proprietary ADC technology.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, President and CEO of Samsung Biologics.
“We’re pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field,” said Philipp Spycher, Ph.D., chief executive officer and co-founder of Araris Biotech. “We look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”
Samsung Life Science Fund, created jointly between Samsung Biologics (KRX: 207940.KS) and Samsung C&T, and managed by Samsung Ventures, makes investment in Araris Biotech AG, a company pioneering a proprietary antibody-drug conjugate (ADC)-linker technology.
The latest investment reflects Samsung Biologics’ commitment to further expand its pipeline and explore new opportunities in biopharmaceuticals, wherein Samsung affiliates will work with Araris to evaluate, manufacture and develop assets using the biotech’s proprietary ADC technology.
“Araris has the potential to develop best-in-class ADC therapies, and we see room for collaboration in the manufacturing and development of new drugs,” said John Rim, President and CEO of Samsung Biologics.
“We’re pleased to receive this support from Samsung, as well as the recognition of the potential of our linker-payload toolbox and conjugation technology in such a quickly growing ADC field,” said Philipp Spycher, Ph.D., chief executive officer and co-founder of Araris Biotech. “We look forward to using these proceeds to further support our efforts in advancing our ADC candidates toward the clinic.”